… two dosing cohorts and is intended to inform next steps in development. We also plan to provide an update from the … Rare Pediatric Disease designation from the Food and Drug Administration (FDA). Granted access to the PRIority … data from the study are expected in 2021. Received Orphan Drug designation and Fast Track designation from the FDA. …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer LEIDEN, the Netherlands, March … Strategy Officer. Dr. Rodman has had a long career in drugdevelopment including leadership roles in translational …
… fibrosis (CF) patients in mid-2017. Investigational new drug (IND) application for QR-110, ProQR’s lead program in … 10 patients. David M. Rodman, MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the … Strategy Officer. Dr. Rodman has had a long career in drugdevelopment including leadership roles in translational …
… held on April 8 - 10 in Monte Carlo, Monaco. World Orphan Drug Congress USA On Thursday, April 26, 2018 at 5:20 pm ET, … companies are ramping up innovation to boost orphan drugdevelopment and patient centricity’ during the World …
